

File Copy
192

DERWENT-ACC-NO: 2002-147883

DERWENT-WEEK: 200235

COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: New isolated human CUB domain containing polypeptide 56739, useful for treating metabolic, immunological, neurological, bone, cardiovascular, liver, pain, viral, cell proliferative and differentiative disorders

INVENTOR-NAME: KAPELLER-LIBERMANN, R

PRIORITY-DATA: 2000US-213963P (June 23, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES
MAIN-IPC			
AU 200177847 A	January 8, 2002	N/A	000
C12N 000/00			
WO 200200843	January 3, 2002	E	107
C12N 000/00			
A2			

INT-CL (IPC): C12N000/00

ABSTRACTED-PUB-NO: WO 200200843A

BASIC-ABSTRACT: NOVELTY - An isolated human CUB (undefined) domain containing polypeptide (I), termed 56739 comprising a sequence (S1) of 418 amino acids fully defined in the specification, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) an isolated nucleic acid (NA) (II) selected from a NA comprising a sequence of 2067 or 1257 base pairs fully defined in the specification, and a NA which encodes (I);
- (2) a host cell (III) containing (II);
- (3) an antibody (IV) which selectively binds (I);
- (4) production of (I);
- (5) detecting (M1) the presence of (II) in a sample by contacting the sample with a nucleic acid probe or primer which selectively hybridizes to (II), and determining whether the probe or primer binds to (II) in the sample;
- (6) a kit (V) comprising a compound which selectively binds to (I) or hybridizes to (II), and instructions for use;
- (7) modulating (M2) the activity of (I) by contacting (I) or a cell expressing (I) with a compound which binds to (I);

(8) inhibiting (M3) the aberrant activity of 56739-expressing cell, by contacting the cell with a compound that modulates the activity or expression of (I) or (II); and

(9) treating (M4) or preventing, in a subject, a disorder characterized by aberrant activity of a 56739-expressing cell, by administering to the subject a compound that modulates the activity or expression of (II).

ACTIVITY - Cytostatic; antidiabetic; antirheumatic; antiarthritic; neuroprotective; antipsoriatic; antiasthmatic; antiallergic; immunosuppressive; nootropic; neuroprotective; antiparkinsonian; osteopathic; hypotensive; antiatherosclerotic; virucide; analgesic.

MECHANISM OF ACTION - Gene therapy; modulator of 56739-mediated activities; modulator of extracellular matrix environment; regulator of developmental processes; modulator of dorsal-ventral polarity; modulator of cell proliferation or differentiation. No supporting data is given.

USE - (IV) is useful for detecting the presence of (I) in a sample by contacting the sample with (IV), and determining whether (IV) binds to (I) in the sample. (I) is useful for identifying a compound which binds to (I) by contacting (I), or a cell expressing (I) with a test compound, and determining whether (I) binds to the test compound (claimed). (I) or (II) is useful for developing novel diagnostic and therapeutic agents for 56739-mediated or related disorders such as cell proliferative and differentiative disorders (e.g., cancer), metabolic disorders (e.g., diabetes mellitus), immunological disorders (e.g., rheumatoid arthritis, multiple sclerosis, psoriasis, Sjogren's syndrome, asthma, allergy, graft-versus-host disease), neurological disorders (Alzheimer's disease, Parkinson's disease), bone disorders (e.g., osteoporosis), cardiovascular disorders (e.g., hypertension, atherosclerosis), liver disorders (e.g., Gaucher's disease), viral diseases, and pain disorders (e.g., headaches). (I), (II) or (IV) is useful in screening assays, detection assays (e.g., chromosomal mapping, tissue typing, forensic biology), predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials and pharmacogenomics), and in methods of treatment (e.g., therapeutic and prophylactic). (I) or (IV) is useful as reagents or targets in assays applicable to treatment and diagnosis of 56739-mediated or related disorders. (I) or (II) is useful as query sequences to perform a search against

public
databases to, for e.g., identify other family members or related
sequences.
(I) is useful as an immunogen to generate antibodies that bind (I). (I)
is
useful to screen for naturally occurring 56739 substrates, and to screen
for
drugs or compounds which modulate 56739 activity. (I) is useful as a
bait
protein in a yeast two-hybrid or three-hybrid assay and to identify other
proteins which bind to or interact with 56739 and or involved in the
56739
activity. (II) is useful as hybridization probe to identify (II), or as
polymerase chain reaction (PCR) primer for the amplification or mutation
of
(II). (II) is useful in gene therapy, to express (I), to detect 56739
mRNA or
a genetic alteration in a 56739 gene, and to modulate 56739 activity.
(II) is
useful to map their respective genes on a chromosome, e.g. to locate gene
regions associated with genetic disease or to associate 56739 with the
disease,
to identify an individual from a minute biological sample (tissue
typing), and
to aid in forensic identification of the biological sample. (IV) is
useful to
isolate and purify (I), to detect (I) and to diagnostically monitor
protein
levels in tissue as part of a clinical testing procedure.

File Copy

DERWENT-ACC-NO: 2000-664924

DERWENT-WEEK: 200237

COPYRIGHT 1999 DERWENT INFORMATION LTD

TITLE: Polypeptide expressed in mammalian fsn -/- lymph node stromal cells,

useful for modulating growth of blood cells, for treating inflammatory and

tumor necrosis factor-mediated disorders, cancer and viral disorders

INVENTOR-NAME: ABERNETHY, N; KUMBLE, K D ; MURISON, J G ; ONRUST, R ; SLEEMAN,

M ; STRACHAN, L ; KUMBLE, A ; MURISON, G

PRIORITY-DATA: 1999US-0383586 (August 26, 1999) , 1999US-0276268 (March 25, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES
MAIN-IPC			
US 20020058335	May 16, 2002	N/A	000
C12N 005/06			
A1	October 5, 2000	E	074
C12N 015/12			
WO 200058463	October 16, 2000	N/A	000
C12N 015/12			
A1	June 5, 2001	N/A	000
A01N 037/18			
AU 200027021 A	December 19, 2001	E	000
C12N 015/12			
US 6242419 B1			
EP 1163334 A1			

INT-CL (IPC): A01N037/18; A61K038/00 ; A61K038/16 ; A61K038/18 ; A61K048/00 ; C07H021/04 ; C07K014/50 ; C12N005/06 ; C12N015/12

ABSTRACTED-PUB-NO: US 6242419B

BASIC-ABSTRACT: NOVELTY - An isolated polypeptide (I) expressed in lymph node

stromal cells of fsn -/- mice, comprising a sequence selected from 26 defined

and given in the specification e.g. 196, 174, 268, 439, 322, 574, 464, 199, 757

or 925 amino acids, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an isolated polynucleotide (II) that encodes (I) comprising a sequence (or its complement, reverse complement or sequences of 40%, 60%, 75% or 90% identity as determined using the computer algorithm BLASTN (basic local alignment search tool)) selected from 26 defined and given in the specification e.g. 803, 689, 1197, 1131, 478, 1742, 1587, 2435, 1008, 925 and 3767 base pairs (bp);

(2) an isolated polynucleotide comprising a sequence selected from a

sequence

that is a 200-mer, 100-mer and 40-mer of (II);

(3) an expression vector (III) comprising (II);

(4) a host cell (IV) transformed with (III); and

(5) a pharmaceutical composition (V) comprising (I) or (II).

ACTIVITY - Cytostatic; antiinflammatory; anti-HIV (human immunodeficiency virus); antiarthritic; cardiant; virucide; dermatological; immunosuppressive; angiogenic.

No biological data is given.

MECHANISM OF ACTION - Vaccine; gene therapy.

No biological data is given.

USE - (V) is useful for treating an inflammatory disorder, disorder of immune system and cancer selected from epithelial, lymphoid, myeloid, stromal and neuronal cancers, a viral disorder, in particular HIV-infection and for modulating the growth of blood vessels. (I) is useful for treating a tumor necrosis factor (TNF) mediated disorder selected from arthritis, inflammatory bowel disease and cardiac failure and a fibroblast growth factor-mediated disorder. (I) is also useful in assays to determine biological activity, to raise antibodies, to isolate corresponding ligands or receptors, to quantify levels of protein or cognate corresponding ligand or receptors, as antiinflammatory agents, and in compositions for the treatment of skin, connective tissue and immune system diseases. (II) is useful as marker for tissue, as a chromosome marker or tags in the identification of a genetic disorder.

ABSTRACTED-PUB-NO: US20020058335A

EQUIVALENT-ABSTRACT: NOVELTY - An isolated polypeptide (I) expressed in lymph node stromal cells of fsn -/- mice, comprising a sequence selected from 26 defined and given in the specification e.g. 196, 174, 268, 439, 322, 574, 464, 199, 757 or 925 amino acids, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) an isolated polynucleotide (II) that encodes (I) comprising a sequence (or its complement, reverse complement or sequences of 40%, 60%, 75% or 90% identity as determined using the computer algorithm BLASTN (basic local alignment search tool)) selected from 26 defined and given in the

specification
e.g. 803, 689, 1197, 1131, 478; 1742, 1587, 2435, 1008, 925 and 3767 base
pairs
(bp);

(2) an isolated polynucleotide comprising a sequence selected from a
sequence
that is a 200-mer, 100-mer and 40-mer of (II);

(3) an expression vector (III) comprising (II);

(4) a host cell (IV) transformed with (III); and

(5) a pharmaceutical composition (V) comprising (I) or (II).

ACTIVITY - Cytostatic; antiinflammatory; anti-HIV (human immunodeficiency
virus); antiarthritic; cardiant; virucide; dermatological;
immunosuppressive;
angiogenic.

No biological data is given.

MECHANISM OF ACTION - Vaccine; gene therapy.

No biological data is given.

USE - (V) is useful for treating an inflammatory disorder, disorder of
immune
system and cancer selected from epithelial, lymphoid, myeloid, stromal
and
neuronal cancers, a viral disorder, in particular HIV-infection and for
modulating the growth of blood vessels. (I) is useful for treating a
tumor
necrosis factor (TNF) mediated disorder selected from arthritis,
inflammatory
bowel disease and cardiac failure and a fibroblast growth factor-mediated
disorder. (I) is also useful in assays to determine biological activity,
to
raise antibodies, to isolate corresponding ligands or receptors, to
quantify
levels of protein or cognate corresponding ligand or receptors, as
antiinflammatory agents, and in compositions for the treatment of skin,
connective tissue and immune system diseases. (II) is useful as marker
for
tissue, as a chromosome marker or tags in the identification of a genetic
disorder.

NOVELTY - An isolated polypeptide (I) expressed in lymph node stromal
cells of
fsn -/- mice, comprising a sequence selected from 26 defined and given in
the
specification e.g. 196, 174, 268, 439, 322, 574, 464, 199, 757 or 925
amino
acids, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the
following:

(1) an isolated polynucleotide (II) that encodes (I) comprising a sequence (or its complement, reverse complement or sequences of 40%, 60%, 75% or 90% identity as determined using the computer algorithm BLASTN (basic local alignment search tool)) selected from 26 defined and given in the specification
e.g. 803, 689, 1197, 1131, 478, 1742, 1587, 2435, 1008, 925 and 3767 base pairs (bp);

(2) an isolated polynucleotide comprising a sequence selected from a sequence that is a 200-mer, 100-mer and 40-mer of (II);

(3) an expression vector (III) comprising (II);

(4) a host cell (IV) transformed with (III); and

(5) a pharmaceutical composition (V) comprising (I) or (II).

ACTIVITY - Cytostatic; antiinflammatory; anti-HIV (human immunodeficiency virus); antiarthritic; cardiant; virucide; dermatological; immunosuppressive; angiogenic.

No biological data is given.

MECHANISM OF ACTION - Vaccine; gene therapy.

No biological data is given.

USE - (V) is useful for treating an inflammatory disorder, disorder of immune system and cancer selected from epithelial, lymphoid, myeloid, stromal and neuronal cancers, a viral disorder, in particular HIV-infection and for modulating the growth of blood vessels. (I) is useful for treating a tumor necrosis factor (TNF) mediated disorder selected from arthritis, inflammatory bowel disease and cardiac failure and a fibroblast growth factor-mediated disorder. (I) is also useful in assays to determine biological activity, to raise antibodies, to isolate corresponding ligands or receptors, to quantify levels of protein or cognate corresponding ligand or receptors, as antiinflammatory agents, and in compositions for the treatment of skin, connective tissue and immune system diseases. (II) is useful as marker for tissue, as a chromosome marker or tags in the identification of a genetic disorder.